Neurosoft Bioelectronics announced that it secured $7.5 million in an oversubscribed seed funding round.
Geneva, Switzerland-based Neurosoft, which has its U.S. operations in New York, continues to advance clinical trials across both the U.S. and Europe for its brain-computer interface (BCI) technology.
Related: Cagent Vascular closes $41M Series D, reports first-in-human IVL cases
The round, led by Skybound Venture Capital, brings the company’s total funding to more than $20 million to date. PL Capital, IAG Capital Partners and Connecticut Innovations, among others, also participated.
Neurosoft is developing minimally invasive, fully implantable BCI systems that leverage state-of-the-art soft materials engineering and artificial intelligence to restore function in people with tinnitus, epilepsy and other disorders.
The technology enables access to the full cortex without penetrating brain tissue. It has proprietary soft, stretchable electrodes that cover more of the cortex than other BCIs, the company says, requiring just a minimally invasive procedure.
With the funding, Neurosoft plans to advance its near-term milestones, including demonstrating minimally invasive deployment in human patients and achieving U.S. commercialization of its first BCI. It also hopes to build a scalable platform and train a foundational model on its neural recordings.
The company also now leverages the Science BCI Ecosystem to eliminate costs and complexities associated with custom hardware development. It already reports 10 human implants across two ongoing clinical trials for its system.
Nicolas Vachicouras, CEO and co-founder of Neurosoft Bioelectronics, said:
“Our soft electrode platform, paired with a streamlined regulatory pathway, gives us access to neural data at a quality and scale no other approach can safely match today. That data is the foundation for improved clinical outcomes, and a cortical foundation model that will help shape the next generation of brain interfaces. The investor support we’ve seen in this round validates that we’re on the right path.”
George Varvarelis, GP at Skybound Venture Capital, said:
“Neurosoft isn’t just building a medical device; they are building the definitive interface between the human mind and the digital world. Their stretchable, sub-millimeter electrodes are a feat of engineering that finally allows us to interface seamlessly with the brain without damaging it. We are proud to lead this investment to accelerate their mission of treating devastating conditions like severe tinnitus and epilepsy, while simultaneously gathering the unprecedented neural data required to map and decode the human cortex at scale.”
